24/7 Market News Snapshot 26 June, 2025 – Altimmune, Inc. Common Stock (NASDAQ:ALT)

June 26, 2025

DENVER, Colo., 26 June, 2025 (www.247marketnews.com) – (NASDAQ:ALT) are discussed in this article.
Altimmune, Inc. is currently facing considerable challenges in the market, with its stock price down to approximately $4.683, reflecting a significant decline of around 39.26% from the previous close of $7.710. This downturn is characterized by a trading volume of 3.55 million shares, which indicates strong selling pressure and investor apprehension. Analysts are closely observing key support levels near $4.50, as a breach of this mark could lead to further declines. Conversely, resistance is noted at the previous closing price, which may present obstacles for any potential recovery.

In the midst of this bearish sentiment, Altimmune has reported promising topline results from the Phase 2b IMPACT trial of pemvidutide, focused on treating metabolic dysfunction-associated steatohepatitis (MASH). The trial saw participation from 212 individuals, revealing a notable efficacy in MASH resolution without fibrotic worsening in up to 59.1% of cases within a 24-week period, a stark contrast to the 19.1% in the placebo group. Additionally, the study indicated that participants administered the higher dose of pemvidutide experienced an average weight loss of 6.2%, compared to just 1.0% in the placebo cohort.

The safety profile of pemvidutide is also noteworthy, with a low discontinuation rate of 1.2% due to adverse events, highlighting its potential as a viable treatment option. Moreover, an AI-based analysis revealed significant reductions in liver fibrosis, further supporting the therapeutic promise of this innovative peptide-based treatment.

Dr. Vipin K. Garg, President and CEO of Altimmune, emphasized the study’s role in advancing MASH therapies and expressed optimism regarding the upcoming FDA regulatory meeting. The encouraging trial results pave the way for future Phase 3 studies, with the goal of addressing a condition anticipated to impact over 27 million individuals by 2030.

Related news for (ALT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.